HUYABIO International, LLC
10Patents
10Active
10Granted
63Portfolio score
Filing activity: Aug 14, 2019 → Dec 19, 2023
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11364223B2 | Sulcardine administration for treatment of acute atrial fibrillation | Human Necessities | 1 | Active |
| US11883380B2 | Sulcardine administration for treatment of acute atrial fibrillation | Human Necessities | 0 | Active |
| US11426382B2 | Sulcardine salts | Chemistry; Metallurgy | 0 | Active |
| US12097203B2 | Combination therapies comprising SHP2 inhibitors and PD-1 inhibitors | Human Necessities | 0 | Active |
| US12054478B2 | Compositions and methods for inhibiting phenyl triazole MLL1-WDR5 protein-protein interaction | Chemistry; Metallurgy | 0 | Active |
| US12357611B2 | Sulcardine administration for treatment of acute atrial fibrillation | Human Necessities | 0 | Active |
| US12122833B2 | Combination therapies of HDAC inhibitors and PD-1 inhibitors | Chemistry; Metallurgy | 0 | Active |
| US12390469B2 | SHP2 inhibitor monotherapy and uses thereof | Human Necessities | 0 | Active |
| US11535670B2 | Combination therapies of HDAC inhibitors and PD-L1 inhibitors | Chemistry; Metallurgy | 0 | Active |
| US11813245B2 | Sulcardine administration for treatment of acute atrial fibrillation | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.